The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

M. E. Gore; E. Galligioni; C. W. Keen; R. Sorio; E. M. Loriaux; H. C. Grobben; C. R. Franks

doi:10.1016/0959-8049(94)90251-8

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

M. E. Gore, E. Galligioni, C. W. Keen, R. Sorio, E. M. Loriaux, H. C. Grobben, C. R. Franks

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

Original language	English
Pages (from-to)	329-333
Number of pages	5
Journal	European Journal of Cancer
Volume	30
Issue number	3
DOIs	https://doi.org/10.1016/0959-8049(94)90251-8
Publication status	Published - 1994

Keywords

interleukin-2
renal cell carcinoma

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/0959-8049(94)90251-8

Cite this

@article{0da8614c1fee49519d331b86eeede8cc,

title = "The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2",

abstract = "Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.",

keywords = "interleukin-2, renal cell carcinoma",

author = "Gore, {M. E.} and E. Galligioni and Keen, {C. W.} and R. Sorio and Loriaux, {E. M.} and Grobben, {H. C.} and Franks, {C. R.}",

year = "1994",

doi = "10.1016/0959-8049(94)90251-8",

language = "English",

volume = "30",

pages = "329--333",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

AU - Gore, M. E.

AU - Galligioni, E.

AU - Keen, C. W.

AU - Sorio, R.

AU - Loriaux, E. M.

AU - Grobben, H. C.

AU - Franks, C. R.

PY - 1994

Y1 - 1994

N2 - Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

AB - Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

KW - interleukin-2

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028234853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028234853&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)90251-8

DO - 10.1016/0959-8049(94)90251-8

M3 - Article

C2 - 8204354

AN - SCOPUS:0028234853

VL - 30

SP - 329

EP - 333

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this